Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Nivolumab × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

INDUSTRY 35 OTHER 20 NIH 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3 Gastrointestinal 2 Tumor-Agnostic 1 Plasma cell 1 Other solid neoplasm 1 Dermatologic 1

Conditions

Advanced Solid Tumors 1

Interventions

Cisplatin 6 Pemetrexed 5 Standard of Care 3 Practice Guidelines as Topic 3 Interviews as Topic 3 Immunoenzyme Techniques 3 Docetaxel 3 Carboplatin 3 N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide 2 Immunohistochemistry 2 Gemcitabine 2 Early Intervention, Educational 2 Bortezomib 2 AEG 35156 2 temsirolimus 1 sabarubicin 1 raltitrexed 1 pembrolizumab 1 nintedanib 1 ascrinvacumab 1 Vincristine 1 Triptorelin Pamoate 1 Trabectedin 1 Thrombopoietin 1 Specimen Handling 1 SB939 compound 1 Reverse Transcriptase Polymerase Chain Reaction 1 Radiotherapy 1 Organizational Objectives 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03461952 2024-02-22

NIMBLe

Canadian Cancer Trials Group

Phase 2 Terminated

4 enrolled 4 charts

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡